Part D Success Enhances Pharma’s Political Effectiveness, Execs Predict
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry gained enhanced bargaining position and improved image - advantages in future health care reform debates, Merck’s Clark and Schering-Plough’s Hassan say.
You may also be interested in...
Medicare Drug Price Debate May Reemerge After Election, BIO Fears
The biotech association is comfortable with both presidential candidates, but concerned that they appear to support a heavier government hand in the Part D benefit.
Medicare Drug Price Debate May Reemerge After Election, BIO Fears
The biotech association is comfortable with both presidential candidates, but concerned that they appear to support a heavier government hand in the Part D benefit.
Medicare Part D Rebates Will Top 9 Percent Of Drug Costs, Medicare Trustees Project
Rebates continue to be higher than predicted, trustees say; Part D is “adequately financed under current law.”